CSF3 and incontinentia pigmenti: Among the 3 available patient-related risk factors, 6 disease-related risk factors and 3 drug-related risk factors, it was found that only drug-related risk factors were significantly associated with IP development: pegylated liposomes doxorubicin (PLD) replacement (RR = 3.25, 95% CI = 1.69-6.27, <i>I<sup>2 =</sup></i> 64%), rituximab (RTX) addition (RR = 4.24, 95% CI = 2.58-6.96, <i>I<sup>2 =</sup></i> 0) and granulocyte colony stimulating factor (G-CSF) administration (RR = 5.80, 95% CI = 3.05-11.05, <i>I<sup>2 =</sup></i> 0).